PR Newswire Clinical TrialsOriginal article
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
PartnershipIDE892RG6620Positive
AI Analysis
Summary
IDEAYA Biosciences announced a clinical collaboration with Genentech to evaluate IDE892 (PRMT5 inhibitor) combined with RG6620 (KRAS G12D inhibitor) in patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma.
Clinical Trial Data
Phase
Phase 1
Importance:6/10
Sentiment:
0.60
clinical collaborationcombination therapypancreatic cancerKRAS G12DMTAP-deletedPRMT5 inhibitor
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 19, 2026 10:00 AM